NCT02968914 - Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

January 4, 2017

Primary Completion Date

July 13, 2017

Study Completion Date

July 13, 2017

Conditions

AsthmaChronic Obstructive Pulmonary Disease

Interventions

BIOLOGICAL

Benralizumab

A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.

BIOLOGICAL

Benralizumab

A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.

Trial Locations (2)

Research Site, Berlin

Research Site, Harrow